

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



EXTRAWELL PHARMACEUTICAL HOLDINGS LIMITED

精優藥業控股有限公司*

(Incorporated in Bermuda with limited liability)

(Stock Code: 00858)

**DELAY IN DESPATCH OF CIRCULAR
IN RELATION TO THE MAJOR TRANSACTION
EXTENSION OF LOAN AGREEMENT
AND
PROVISION OF FINANCIAL ASSISTANCE**

Reference is made to the announcement of Extrawell Pharmaceutical Holdings Limited (the “**Company**”) dated 30 July 2024 (the “**Announcement**”) relating to, among others, the extension of loan agreement and provision of financial assistance. Unless otherwise specified, capitalised terms used in this announcement shall have the same meanings as set out in the Announcement.

As stated in the Announcement, a circular (the “**Circular**”) containing, among others, (i) details of the First Loan Extension Agreement and the Third Shareholders’ Loan Agreement and the transactions contemplated thereunder; (ii) other information required under the Listing Rules; and (iii) notice of the SGM will be despatched to the Shareholders on or before 13 September 2024.

As additional time is required to prepare and finalise certain information to be included in the Circular, the date of despatch of the Circular is expected to be postponed to a date on or before 30 September 2024.

By order of the Board
Extrawell Pharmaceutical Holdings Limited
Xie Yi
Chairman

Hong Kong, 13 September 2024

As at the date of this announcement, the executive directors are Dr. Xie Yi, Mr. Cheng Yong, Dr. Lou Yi, Ms. Wong Sau Kuen and Dr. Guo Yi, and the independent non-executive directors are Mr. Fang Lin Hu, Ms. Jin Song and Dr. Zeng Li.

* *For identification purpose only*